{"id":"W4310162547","doi":"10.1182/blood-2022-159000","title":"Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Cyclophosphamide; Regimen; Chemotherapy regimen; Phases of clinical research; Interim analysis; Clinical trial; Chemotherapy; Surgery; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003015196,0.002846833,0.003397647,0.000504988,0.00055367,0.001868198,0.001383692,0.002430277,0.007505272],"category_scores_gemma":[0.001556577,0.0009164372,0.001770229,0.0004749786,0.001907682,0.001965305,0.0007351738,0.004221102,0.001544504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001277256,"about_ca_system_score_gemma":0.001800929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006360466,"about_ca_topic_score_gemma":0.001808311,"domain_scores_codex":[0.9992704,0.0003325971,0.00002415588,0.0001671083,0.00005850857,0.0001472891],"domain_scores_gemma":[0.9992504,0.0001341867,0.0001688162,0.00008206167,0.00005613952,0.0003084704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9475591,0.02337055,0.0009064222,0.0007911796,0.0007280761,0.00006730846,0.0001026171,0.000705014,0.007209387,0.000382611,0.002193828,0.01598377],"study_design_scores_gemma":[0.9145222,0.08169252,0.0009967664,0.00002106424,0.0002212317,0.00004780467,0.00002396635,0.0004042209,0.0005068475,0.0002754426,0.001271755,0.00001635922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648983,0.004994303,0.002277574,0.001760619,0.001347237,0.01592093,0.003710414,0.0005154537,0.004575082],"genre_scores_gemma":[0.9420756,0.00342175,0.006225791,0.003735751,0.001098332,0.02679393,0.004475517,0.000154467,0.01201892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007505272,"threshold_uncertainty_score":0.02510762,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01516895718212246,"score_gpt":0.2640527694870936,"score_spread":0.2488838123049711,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}